TAXOMET: A French Prospective Multicentric Randomized Phase II Study of Docetaxel Plus Metformin Versus Docetaxel Plus Placebo in Metastatic Castration-Resistant Prostate Cancer.

MLA

Martin, Marc Pujalte, et al. “TAXOMET: A French Prospective Multicentric Randomized Phase II Study of Docetaxel Plus Metformin Versus Docetaxel Plus Placebo in Metastatic Castration-Resistant Prostate Cancer.” Clinical Genitourinary Cancer, vol. 19, no. 6, Dec. 2021, pp. 501–09. EBSCOhost, https://doi.org/10.1016/j.clgc.2021.08.008.

APA

Martin, M. P., Borchiellini, D., Thamphya, B., Guillot, A., Paoli, J.-B., Besson, D., Hilgers, W., Priou, F., El Kouri, C., Hoch, B., Deville, J.-L., Schiappa, R., Cheli, S., Milano, G., Tanti, J.-F., Bost, F., & Ferrero, J.-M. (2021). TAXOMET: A French Prospective Multicentric Randomized Phase II Study of Docetaxel Plus Metformin Versus Docetaxel Plus Placebo in Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 19(6), 501–509. https://doi.org/10.1016/j.clgc.2021.08.008

Chicago

Martin, Marc Pujalte, Delphine Borchiellini, Brice Thamphya, Aline Guillot, Jean-Baptiste Paoli, Dominique Besson, Werner Hilgers, et al. 2021. “TAXOMET: A French Prospective Multicentric Randomized Phase II Study of Docetaxel Plus Metformin Versus Docetaxel Plus Placebo in Metastatic Castration-Resistant Prostate Cancer.” Clinical Genitourinary Cancer 19 (6): 501–9. doi:10.1016/j.clgc.2021.08.008.